CL2017001818A1 - Bacteria de ácido láctico y su uso para el tratamiento de mastitis - Google Patents

Bacteria de ácido láctico y su uso para el tratamiento de mastitis

Info

Publication number
CL2017001818A1
CL2017001818A1 CL2017001818A CL2017001818A CL2017001818A1 CL 2017001818 A1 CL2017001818 A1 CL 2017001818A1 CL 2017001818 A CL2017001818 A CL 2017001818A CL 2017001818 A CL2017001818 A CL 2017001818A CL 2017001818 A1 CL2017001818 A1 CL 2017001818A1
Authority
CL
Chile
Prior art keywords
lactic acid
mastitis
treatment
lactobacillus reuteri
acid bacterium
Prior art date
Application number
CL2017001818A
Other languages
English (en)
Inventor
Eamonn Connolly
Bo Möllstam
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia Ab filed Critical Biogaia Ab
Publication of CL2017001818A1 publication Critical patent/CL2017001818A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)

Abstract

<p>La presente invención se refiere a nuevas cepas de Bacterias Ácido Lácticas Lactobacillus reuteri seleccionadas del grupo que comprende Lactobacillus reuteri DSM 32229, Lactobacillus reuteri DSM 32230, Lactobacillus reuteri DSM 32231 y Lactobacillus reuteri DSM 32232 y productos que comprenden estas cepas. La presente invención también se refiere a un uso de una o más cepas de Bacterias Ácido Lácticas como un probiótico para el tratamiento de una inflamación e infección, tal como la mastitis y/o la candidiasis bucal, especialmente después de la administración tópica de dichas cepas.</p>
CL2017001818A 2015-01-16 2017-07-12 Bacteria de ácido láctico y su uso para el tratamiento de mastitis CL2017001818A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562104164P 2015-01-16 2015-01-16

Publications (1)

Publication Number Publication Date
CL2017001818A1 true CL2017001818A1 (es) 2018-03-02

Family

ID=56405271

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001818A CL2017001818A1 (es) 2015-01-16 2017-07-12 Bacteria de ácido láctico y su uso para el tratamiento de mastitis

Country Status (12)

Country Link
US (2) US20180273895A1 (es)
EP (1) EP3244904A1 (es)
JP (1) JP2018504902A (es)
KR (1) KR20170103804A (es)
CN (1) CN107532137A (es)
AU (1) AU2016208009A1 (es)
BR (1) BR112017014225A2 (es)
CA (1) CA2972967A1 (es)
CL (1) CL2017001818A1 (es)
HK (1) HK1248756A1 (es)
MX (1) MX2017007969A (es)
WO (1) WO2016113365A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700062260A1 (it) * 2017-06-07 2018-12-07 Proge Farm Srl Associazione e composizioni topiche cutanee comprendenti lattobacilli e ossidi metallici e/o semimetallici
WO2020132098A1 (en) * 2018-12-19 2020-06-25 Healthy Cow Corporation Ready-to-use probiotic compositions and uses thereof
KR20220066269A (ko) * 2019-09-26 2022-05-24 프리시젼바이오틱스 그룹 리미티드 락토바실러스 루테리
CA3186421A1 (en) * 2020-06-30 2022-01-06 Biogaia Ab Probiotic composition for topical use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7955834B2 (en) * 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
EP1997499A1 (en) * 2007-05-31 2008-12-03 Puleva Biotech, S.A. Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis
US20130022586A1 (en) * 2011-07-21 2013-01-24 James Versalovic Production and use of bacterial histamine
US20140370153A1 (en) * 2011-12-30 2014-12-18 Abbott Laboratories Concentrated low water activity liquid human milk fortifier including extensively hydrolyzed protein

Also Published As

Publication number Publication date
US20180273895A1 (en) 2018-09-27
BR112017014225A2 (pt) 2018-03-06
CN107532137A (zh) 2018-01-02
AU2016208009A1 (en) 2017-07-20
EP3244904A1 (en) 2017-11-22
MX2017007969A (es) 2018-04-10
US20200318061A1 (en) 2020-10-08
JP2018504902A (ja) 2018-02-22
HK1248756A1 (zh) 2018-10-19
KR20170103804A (ko) 2017-09-13
WO2016113365A1 (en) 2016-07-21
CA2972967A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
MX2016009898A (es) Tratamientos para acne resistente.
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
MX2019004611A (es) Metodos y composiciones para cambiar la composicion del microbioma de la piel usando mezclas complejas de cepas bacterianas.
CL2019002640A1 (es) Moléculas propioticas para reducir virulencia de patógenos.
CL2017001818A1 (es) Bacteria de ácido láctico y su uso para el tratamiento de mastitis
PE20181133A1 (es) Bacteria lactobacillus fermentum con actividad antifungica
PH12016501988A1 (en) Antibacterial compounds
MX2017012073A (es) Compuestos de minociclina para biodefensas.
CL2018001936A1 (es) Nueva cepa bacteriana probiótica de lactobacillus plantarum y composiciones y usos de la misma en el tratamiento de la inflamación.
MX2017004569A (es) Inhibidores de gingipaina de lisina.
MX2017009094A (es) Derivado de polimixina y usos del mismo.
MX2016016885A (es) Administracion in ovo de cultivos probioticos.
EP4241851A3 (en) Immunogenic compositions
PH12018500358A1 (en) Compounds for use in an antibacterial applications
PH12016501532A1 (en) Antibacterial combinations comprising polymyxin
WO2016191695A3 (en) Treatments for obligately intracellular infections
MX2019006086A (es) Uso de una composicion bacteriana para tratar infecciones en las patas de ungulados.
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
TR201907851T4 (tr) Örn. bakteriyel vajinozis tedavisine yönelik lactobacillus rhamnosus bakterisi.
AR103086A1 (es) Composiciones y métodos para reducir las infecciones en aves de corral
UY35631A (es) ?composición de solución de rehidratación oral que contiene probióticos?.
BR112016029761A8 (pt) composições compreendendo um derivado de ácido quinolona carboxílico e agentes efervescentes, uso das mesmas e forma cristalina do referido derivado